Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
CT Su, JC Ye - Journal of Hematology & Oncology, 2021 - Springer
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the
advent of monoclonal antibodies and the approval of novel agents with new mechanisms of …
advent of monoclonal antibodies and the approval of novel agents with new mechanisms of …
Allogeneic CAR T Cell Therapy for Cancer
BJ Sasu, EJ Lauron, T Schulz… - Annual Review of …, 2023 - annualreviews.org
Autologous chimeric antigen receptor (CAR) T cell therapy, produced from the patient's own
T cells, has changed the treatment landscape for hematologic malignancies but has some …
T cells, has changed the treatment landscape for hematologic malignancies but has some …
Expert perspective: Highlights on myeloma cell therapy from the American Society of Hematology Annual Meeting 2019
C Kunacheewa, EE Manasanch - Advances in Cell and Gene …, 2020 - Wiley Online Library
Autologous stem cell transplantation has been part of standard of treatment in multiple
myeloma for 2 decades. The data showed improving progression‐free survival and overall …
myeloma for 2 decades. The data showed improving progression‐free survival and overall …
T Cell Immunotherapy of Cancer
ML Palomba, JH Park… - Holland‐Frei Cancer …, 2016 - Wiley Online Library
Overview Bone marrow transplantation (BMT) represents the first known example of using
the anti‐tumor potential of T cells; a phenomenon later known as the graft versus tumor …
the anti‐tumor potential of T cells; a phenomenon later known as the graft versus tumor …